|
| Press Releases |
|
 |
|
| Wednesday, September 5, 2018 |
|
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
| Friday, July 27, 2018 |
|
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
| Friday, June 22, 2018 |
|
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
| Wednesday, June 6, 2018 |
|
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
| Friday, May 4, 2018 |
|
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
| Wednesday, April 18, 2018 |
|
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
| Wednesday, April 11, 2018 |
|
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
| Friday, March 30, 2018 |
|
|
Nanobiotix 2017 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
| Monday, January 22, 2018 |
|
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
| Thursday, January 11, 2018 |
|
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Honda、原付二種スポーツモデル「グロム」のカラーバリエーションを変更し発売
May 15, 2026 11:50: JST
|
|
|
Honda、「Honda E-Clutch」を搭載した「CBR400R E-Clutch」「NX400 E-Clutch」を発売
May 15, 2026 11:50: JST
|
|
|
富士通と日本IBM、ヘルスケア領域における協業を具体化
May 15, 2026 10:15: JST
|
|
|
Wellgistics Health 透過計劃收購 WellCare Today 及其專屬的 Samsung Galaxy Watch 照護監測計畫，加速其新近宣布的遠端患者監測（RPM）、遠端治療管理（RTM）及慢性病管理（CCM）試點計畫的數位健康擴展
May 15, 2026 07:00 HKT/SGT
|
|
|
Wellgistics Health 计划收购 WellCare Today 及其专有的三星 Galaxy Watch 护理监测项目，以此加速其新近宣布的远程患者监测（RPM）、远程治疗管理（RTM）和慢性病管理（CCM）试点项目的数字健康业务拓展
May 15, 2026 07:00 HKT/SGT
|
|
|
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program
May 15, 2026 07:00 HKT/SGT
|
|
|
JCB and Discover(R) Network Mark 20 Years of Collaboration
May 14, 2026 23:00 JST
|
|
|
Galaxy Payroll Group Limited中期業績顯著改善 經營現金流轉正
May 14, 2026 16:06 HKT/SGT
|
|
|
Asset Value Investors (AVI) urges the dismissal of two directors at Wacom
May 14, 2026 17:00 JST
|
|
|
Galaxy Payroll Group Limited Reports Improved Interim Results and Positive Operating Cash Flow
May 14, 2026 15:44 HKT/SGT
|
|
|
金山科技签订6.75亿绿色及可持续发展表现挂钩贷款
May 14, 2026 15:03 HKT/SGT
|
|
|
TOYOTA、ランドクルーザー 新型車“FJ”シリーズを発売
May 14, 2026 14:30: JST
|
|
|
Honda、インドにおいてデジタルサービスを提供する新会社を設立
May 14, 2026 14:30: JST
|
|
|
AIがブランド発見のあり方を変革する中、AssemblyがAPAC全域で「Stagwell Search+」を展開
May 14, 2026 13:00: JST
|
|
|
Euro Manganese Announces Positive Preliminary Economic Assessment
May 14, 2026 12:29 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
